"This is a major milestone for the Quell brand," said Frank McGillin, SVP and Chief Commercial Officer. "We are excited that our patented, 100% drug free technology is making a difference for a growing number of people suffering from chronic pain. There is a building awareness of Quell from media coverage in high profile outlets including Fox 25 News and Bloomberg, as well as our continued investment in TV advertising. Our newest TV ad premiered this week, and highlights how wearable neurotechnology can deliver widespread pain relief. We are pleased with market acceptance of Quell to date and optimistic regarding future growth."
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.
To learn more about NeuroMetrix's 100,000th Quell device milestone, please visit the LivingQuell blog.
NeuroMetrix is a commercial stage, innovation driven healthcare company
combining neurostimulation and digital medicine to address chronic
health conditions including chronic pain, sleep disorders, and diabetes.
The company's lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. Quell is integrated into a digital
health platform that helps patients optimize their therapy and decrease
the impact of chronic pain on their quality of life. The company also
markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has
several pipeline programs. The company is located in Waltham,
SVP and Chief Financial Officer
News Provided by Acquire Media